azzalure 125 speywood-yksikköä injektiokuiva-aine, liuosta varten
institut produits synthese (ipsen) ab - clostridium botulinum toxin type a haemagglutinin complex - injektiokuiva-aine, liuosta varten - 125 speywood-yksikköä - botuliinitoksiini
persantin 75 mg tabletti, päällystetty
glenwood gmbh pharmazeutische erzeugnisse - dipyridamole - tabletti, päällystetty - 75 mg - dipyridamoli
catapresan 150 mikrog tabletti
glenwood gmbh pharmazeutische erzeugnisse - clonidine hydrochloride - tabletti - 150 mikrog - klonidiini
catapresan 150 mikrog/ml injektioneste, liuos
glenwood gmbh pharmazeutische erzeugnisse - clonidine hydrochloride - injektioneste, liuos - 150 mikrog/ml - klonidiini
azzalure 125 speywood-yksikköä injektiokuiva-aine, liuosta varten
orifarm oy - clostridium botulinum toxin type a haemagglutinin complex - injektiokuiva-aine, liuosta varten - 125 speywood-yksikköä - botuliinitoksiini
azzalure 125 speywood-yksikköä injektiokuiva-aine, liuosta varten
paranova oy - bakteerit botulinum toxinum tyyppi hemagglutiniini monimutkainen - injektiokuiva-aine, liuosta varten - 125 speywood-yksikköä - botuliinitoksiini
cialis
eli lilly nederland b.v. - tadalafil - erektiohäiriö - urologiset - erektiohäiriön hoito. jotta tadalafiili olisi tehokas, tarvitaan seksuaalista stimulaatiota. cialis ei ole tarkoitettu naisten käyttöön.
tadalafil lilly
eli lilly nederland b.v. - tadalafil - erektiohäiriö - urologiset - erektiohäiriön hoito aikuisilla miehillä. jotta tadalafiili olisi tehokas, tarvitaan seksuaalista stimulaatiota. tadalafil lilly ei ole tarkoitettu naisten käyttöön. hoitoon oireiden ja eturauhasen hyvänlaatuisen liikakasvun aikuisilla miehillä.
memantine ratiopharm
ratiopharm gmbh - memantiinihydrokloridia - alzheimerin tauti - psychoanaleptics, - alzheimerin taudin keskivaikean tai vaikean potilaan hoito.
ultomiris
alexion europe sas - ravulizumab - hemoglobinuria, paroxysmal - selektiiviset immunosuppressantit - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.